About

Mr. Scodari has served as a director of Acurx since July 2021. Since October 2017 he has been Chairman of the Board of Optinose (Nasdaq: OPTN). He previously served as Worldwide Chairman of Johnson & Johnson's Pharmaceuticals Group and a member of its Executive Committee from March 2005 until his retirement in March 2008, and from 2003 to 2005 as Company Group Chairman of J&J's Biopharmaceutical Business. He joined Centocor Inc. in 1996 as President of its Pharmaceutical Division and was named President and Chief Operating Officer in 1998, serving until Centocor's 1999 acquisition by Johnson & Johnson. He previously served as a director of Actelion Pharmaceuticals, Endo Health Solutions and Covance. Mr. Scodari received a B.A. from Youngstown State University.

Roles

Acurx Pharmaceuticals, Inc.
Director · Current role
July 2021–present
Optinose, Inc.
Chairman of the Board
2017 - present
Johnson & Johnson
Worldwide Chairman, Pharmaceuticals Group & Executive Committee member
2005 - 2008
Johnson & Johnson
Company Group Chairman, Biopharmaceutical Business
2003 - 2005
Centocor, Inc.
President & Chief Operating Officer
1996 - 1999
Rhone-Poulenc Rorer
SVP & General Manager, Americas

External Roles

Actelion Pharmaceuticals, Ltd.
Director
Endo Health Solutions, Inc.
Director
Covance, Inc.
Director

Director Compensation

FY 2024
Fees earned or paid in cash
$57,500
ComponentAnnual cash retainers and committee/leadership fees earned in 2024
Option awards
$22,104
ComponentStock options granted during 2024, ASC 718 grant-date fair value
Total
$79,604

Also at Acurx Pharmaceuticals, Inc.

Related

See how VectorShift works for your firm

Request Demo